ES2621291T3 - Derivados de 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]isoquinolina - Google Patents
Derivados de 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]isoquinolina Download PDFInfo
- Publication number
- ES2621291T3 ES2621291T3 ES14164018.5T ES14164018T ES2621291T3 ES 2621291 T3 ES2621291 T3 ES 2621291T3 ES 14164018 T ES14164018 T ES 14164018T ES 2621291 T3 ES2621291 T3 ES 2621291T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitors
- receptor antagonists
- thiopyran
- tetrahydro
- tetrahydrobiopterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Combinación fijada que comprende 3-[1-({4-[(4aR,10bR)-9-etoxi-8-metoxi-3,4,4a,10b-tetrahidro-1H-tiopirano[4,3- c]isoquinolin-6-il]fenil}carbonil)piperidin-4-il]-1-[(2-etil-2H-tetrazol-5-il)metil]-6-feniltieno[3,2-d]pirimidina-2,4(1H,3H)- diona (en lo sucesivo denominada "Compuesto A"), al menos un agente terapéutico seleccionado del grupo que consiste en corticosteroides, anticolinérgicos, agonistas de adreno-receptor-ß2, antagonistas del receptor H1, antagonistas de los receptores de leucotrieno, inhibidores de 5-lipoxigenasa, antagonistas de los receptores de endotelina, prostaciclinas, bloqueadores del canal de calcio, bloqueadores beta, inhibidores de fosfodiesterasa tipo 4, inhibidores de fosfodiesterasa tipo 5, inmunosupresores, análogos de vitamina D, inhibidores de HMG-CoA-reductasa, tensoactivos pulmonares, antibióticos, activadores/estimuladores de guanilil-ciclasa, tetrahidrobiopterina y derivados de tetrahidrobiopterina, anticoagulantes, diuréticos, pirfenidona y glicósidos digitales, y al menos un auxiliar farmacéuticamente aceptable.
Description
20
25
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7 imagen8 imagen9 imagen10 imagen11 imagen12
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09179982 | 2009-12-18 | ||
EP09179982 | 2009-12-18 | ||
US31555210P | 2010-03-19 | 2010-03-19 | |
US315552P | 2010-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2621291T3 true ES2621291T3 (es) | 2017-07-03 |
Family
ID=41718903
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14164018.5T Active ES2621291T3 (es) | 2009-12-18 | 2010-12-15 | Derivados de 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]isoquinolina |
ES10790569.7T Active ES2505290T3 (es) | 2009-12-18 | 2010-12-15 | Derivados de 3,4,4A,10B-tetrahidro-1H-tiopirano[4,3-c]isoquinolina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10790569.7T Active ES2505290T3 (es) | 2009-12-18 | 2010-12-15 | Derivados de 3,4,4A,10B-tetrahidro-1H-tiopirano[4,3-c]isoquinolina |
Country Status (29)
Country | Link |
---|---|
US (1) | US9018175B2 (es) |
EP (2) | EP2813509B1 (es) |
JP (1) | JP5645961B2 (es) |
KR (1) | KR20120123313A (es) |
CN (1) | CN102652136B (es) |
AR (1) | AR079451A1 (es) |
AU (1) | AU2010332955B8 (es) |
BR (1) | BR112012014058A8 (es) |
CA (1) | CA2784013A1 (es) |
CO (1) | CO6551705A2 (es) |
DK (1) | DK2513119T3 (es) |
EA (1) | EA023212B1 (es) |
ES (2) | ES2621291T3 (es) |
GE (1) | GEP20146105B (es) |
HK (1) | HK1174326A1 (es) |
HR (1) | HRP20140893T1 (es) |
ME (1) | ME01914B (es) |
MX (1) | MX2012006696A (es) |
NZ (1) | NZ601115A (es) |
PL (1) | PL2513119T3 (es) |
PT (1) | PT2513119E (es) |
RS (1) | RS53544B1 (es) |
SG (2) | SG196785A1 (es) |
SI (1) | SI2513119T1 (es) |
SM (1) | SMT201400185B (es) |
TW (1) | TWI468411B (es) |
UA (1) | UA107689C2 (es) |
WO (1) | WO2011073231A1 (es) |
ZA (1) | ZA201204135B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110300432A1 (en) | 2010-06-07 | 2011-12-08 | Snyder Shawn W | Rechargeable, High-Density Electrochemical Device |
RU2013142268A (ru) * | 2011-02-17 | 2015-03-27 | Сипла Лимитед | Фармацевтическая композиция |
EP2721036B1 (en) | 2011-06-15 | 2015-07-22 | Takeda GmbH | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
WO2014016548A2 (en) * | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
WO2014090990A1 (en) * | 2012-12-13 | 2014-06-19 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
AU2014211755B2 (en) | 2013-02-04 | 2017-07-06 | Grunenthal Gmbh | 4-amino substituted condensed pyrimidine compounds as PDE4 inhibitors |
ES2638850T3 (es) | 2013-02-19 | 2017-10-24 | Pfizer Inc. | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos |
JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
WO2016020786A1 (en) | 2014-08-06 | 2016-02-11 | Pfizer Inc. | Imidazopyridazine compounds |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899494A (en) | 1970-05-13 | 1975-08-12 | Sandoz Ltd | Substituted 6-phenyl benzo-naphthyridines |
DE2047465A1 (de) | 1970-09-26 | 1972-03-30 | Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt | Neue Oxdiazole und Verfahren zu lh rer Herstellung |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
JPH01213284A (ja) | 1988-02-22 | 1989-08-28 | Sankyo Co Ltd | チエノピリミジン−2,4−ジオン誘導体 |
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
ATE111364T1 (de) | 1989-05-31 | 1994-09-15 | Fisons Plc | Medikament und inhalationsvorrichtung dafür. |
GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
JPH05505824A (ja) | 1990-03-23 | 1993-08-26 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用 |
ATE114112T1 (de) | 1990-10-18 | 1994-12-15 | Minnesota Mining & Mfg | Aerosolzubereitung, die beclometason 17,21- dipropionat enthält. |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
IL111194A (en) | 1993-10-08 | 1998-02-08 | Fisons Plc | Process for the production of drug patramulations |
ES2195189T3 (es) | 1996-11-11 | 2003-12-01 | Altana Pharma Ag | Benzonaftiridinas como agentes terapeuticos bronquiales. |
ES2179490T3 (es) | 1997-05-08 | 2003-01-16 | Merck Sharp & Dohme | Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5. |
AU8106598A (en) | 1997-06-03 | 1998-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine |
CN1150890C (zh) | 1998-08-04 | 2004-05-26 | 杰格研究股份公司 | 药用气溶胶制剂 |
US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
US6454193B1 (en) | 1999-04-23 | 2002-09-24 | Battellepharma, Inc. | High mass transfer electrosprayer |
BR0009993A (pt) | 1999-04-23 | 2002-01-08 | Battelle Memorial Institute | Pulverizador de aerossol eletrohidrodinâmico direcionalmente controlado, dispositivo para liberar gotìculas de aerossol eletricamente neutras, aparelho para liberar gotìculas de aerossol terapêuticas, processo para liberar gotìculas de aerossol, e, dispositivo para liberar aerossol |
ATE312820T1 (de) | 1999-10-28 | 2005-12-15 | Trine Pharmaceuticals Inc | Pumpeninhibitoren zur freisetzung von medikamenten |
WO2001094350A1 (en) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
AU2001281965A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel 6-phenylphenanthridines |
ES2260299T3 (es) | 2000-10-09 | 2006-11-01 | 3M Innovative Properties Company | Formulaciones medicinales en aerosol. |
EP1425029A4 (en) | 2001-08-10 | 2006-06-07 | Palatin Technologies Inc | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES |
US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
MXPA06012279A (es) | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
JP4960870B2 (ja) | 2004-09-08 | 2012-06-27 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の3−チア−10−アザ−フェナントレン誘導体 |
US7838521B2 (en) | 2004-09-08 | 2010-11-23 | Nycomed Gmbh | 3-oxa-10-aza-phenanthrenes |
EP1813603A1 (en) | 2004-11-17 | 2007-08-01 | Kissei Pharmaceutical Co., Ltd. | Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both |
JP2008532980A (ja) * | 2005-03-09 | 2008-08-21 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミド置換された6−フェニルフェナントリジン |
JP5309131B2 (ja) * | 2007-04-23 | 2013-10-09 | サノフイ | P2y12アンタゴニストとしてのキノリン−カルボキサミド誘導体 |
EP2721036B1 (en) * | 2011-06-15 | 2015-07-22 | Takeda GmbH | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
-
2010
- 2010-12-14 AR ARP100104617A patent/AR079451A1/es unknown
- 2010-12-15 DK DK10790569.7T patent/DK2513119T3/da active
- 2010-12-15 SI SI201030746T patent/SI2513119T1/sl unknown
- 2010-12-15 UA UAA201208482A patent/UA107689C2/ru unknown
- 2010-12-15 ME MEP-2014-114A patent/ME01914B/me unknown
- 2010-12-15 WO PCT/EP2010/069704 patent/WO2011073231A1/en active Application Filing
- 2010-12-15 US US13/515,214 patent/US9018175B2/en not_active Expired - Fee Related
- 2010-12-15 EP EP14164018.5A patent/EP2813509B1/en active Active
- 2010-12-15 SG SG2014000335A patent/SG196785A1/en unknown
- 2010-12-15 AU AU2010332955A patent/AU2010332955B8/en not_active Ceased
- 2010-12-15 EP EP10790569.7A patent/EP2513119B1/en active Active
- 2010-12-15 CA CA2784013A patent/CA2784013A1/en not_active Abandoned
- 2010-12-15 ES ES14164018.5T patent/ES2621291T3/es active Active
- 2010-12-15 CN CN201080057293.7A patent/CN102652136B/zh not_active Expired - Fee Related
- 2010-12-15 RS RSP20140499 patent/RS53544B1/en unknown
- 2010-12-15 EA EA201200891A patent/EA023212B1/ru not_active IP Right Cessation
- 2010-12-15 PL PL10790569T patent/PL2513119T3/pl unknown
- 2010-12-15 GE GEAP201012783A patent/GEP20146105B/en unknown
- 2010-12-15 SG SG2012034732A patent/SG180824A1/en unknown
- 2010-12-15 BR BR112012014058A patent/BR112012014058A8/pt not_active IP Right Cessation
- 2010-12-15 NZ NZ601115A patent/NZ601115A/en not_active IP Right Cessation
- 2010-12-15 JP JP2012543701A patent/JP5645961B2/ja not_active Expired - Fee Related
- 2010-12-15 KR KR1020127017957A patent/KR20120123313A/ko not_active Application Discontinuation
- 2010-12-15 PT PT107905697T patent/PT2513119E/pt unknown
- 2010-12-15 ES ES10790569.7T patent/ES2505290T3/es active Active
- 2010-12-15 MX MX2012006696A patent/MX2012006696A/es active IP Right Grant
- 2010-12-17 TW TW99144591A patent/TWI468411B/zh not_active IP Right Cessation
-
2012
- 2012-05-24 CO CO12085785A patent/CO6551705A2/es active IP Right Grant
- 2012-06-06 ZA ZA2012/04135A patent/ZA201204135B/en unknown
-
2013
- 2013-01-28 HK HK13101194.7A patent/HK1174326A1/xx not_active IP Right Cessation
-
2014
- 2014-09-17 HR HRP20140893AT patent/HRP20140893T1/hr unknown
- 2014-12-11 SM SM201400185T patent/SMT201400185B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2621291T3 (es) | Derivados de 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]isoquinolina | |
CR20210665A (es) | Formas en estado sólido | |
WO2009118759A3 (en) | Heterocyclic compounds as adenosine receptor antagonist | |
HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
PE20081341A1 (es) | Inhibidores de la actividad de la akt | |
JP2013528204A5 (es) | ||
WO2015132799A3 (en) | Heterocyclic compounds | |
RU2006125720A (ru) | Пиперидинаминобензимидазольные производные как ингибиторы репликации респираторного синцитиального вируса | |
WO2015058163A3 (en) | Heteromaromatic compounds useful for the treatment of prolferative diseases | |
WO2015058126A8 (en) | Heteroaromatic compounds useful for the treatment of prolferative diseases | |
TNSN07434A1 (en) | Crystalline and other forms of 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts | |
EA201591239A1 (ru) | Замещенные фталазин-1(2h)-оновые производные в качестве селективных ингибиторов поли(адф-рибоза)полимеразы-1 | |
PE20141197A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
JP2011522866A5 (es) | ||
MA40580B1 (fr) | Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques | |
JP2009517403A5 (es) | ||
NZ597533A (en) | Apoptosis signal-regulating kinase inhibitors | |
NO20082121L (no) | Imidazopyridinderivater som A2B-adenosinreseptorantagonister | |
RU2011100786A (ru) | Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ | |
JP2017512803A5 (es) | ||
MX2017013219A (es) | Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. | |
PH12016500989A1 (en) | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonists | |
MX368157B (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
MX2020013015A (es) | Formulaciones farmaceuticas de inhibidores de cinasa relacionada con tropomiosina (trk). | |
SG11201504164VA (en) | 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST |